A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms LADDER
  • Sponsors Genentech
  • Most Recent Events

    • 12 Oct 2017 Status changed from active, no longer recruiting to recruiting.
    • 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Aug 2017 Planned End Date changed from 1 May 2018 to 31 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top